Breaking News Instant updates and real-time market news.

NFLX

Netflix

$190.12

0.56 (0.30%)

, DIS

Disney

$111.27

0.7 (0.63%)

20:03
12/17/17
12/17
20:03
12/17/17
20:03

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Humana (HUM) is in advanced talks to buy Kindred Healthcare (KND) in partnership with private firms Welsh, Carson, Anderson & Stowe and TPG, according to Reuters. 2. Oracle (ORCL) announced that it has entered into an agreement with Aconex, a leading cloud-based solution that manages team collaboration for construction projects. The transaction is valued at approximately $1.2B, net of Aconex cash. 3. Netflix (NFLX) success and its high valuation is forcing the rest of the TV work to scramble, Alex Eule wrote in this week's edition of Barron's. In the wake of Disney's (DIS) 21st Century Fox (FOXA; FOX) purchase, investors should expect more consolidation to come, he added. Given that FOX RSN business looks very similar to MSG Networks (MSGN) and with Disney's deal spurring a new wave of RSN interest, 208 could be the year that MSG gets sold, Barron's says. Other potential attractive targets include AMC (AMCX) and Viacom (VIAB), Eule contended. 4. Disney and Lucasfilm's "Star Wars: The Last Jedi" opened to a near-record $220M in North America, the second-best showing behind "Star Wars: The Force Awakens." Internationally, the movie took in $230M from 54 markets. "The Last Jedi" received an A CinemaScore and got a 93% from Rotten Tomatoes. 5. Spark Therapeutics (ONCE), Alaska Air (ALK) saw positive mentions in Barron's, while Exxon (XOM) was mentioned cautiously.

NFLX

Netflix

$190.12

0.56 (0.30%)

DIS

Disney

$111.27

0.7 (0.63%)

FOXA

21st Century Fox

$34.99

0.11 (0.32%)

FOX

21st Century Fox

$34.22

(0.00%)

MSGN

MSG Networks

$19.80

0.05 (0.25%)

AMCX

AMC Networks

$55.33

1.16 (2.14%)

VIAB

Viacom

$30.24

0.53 (1.78%)

VIA

Viacom

$34.40

0.25 (0.73%)

XOM

Exxon Mobil

$83.03

0.13 (0.16%)

ONCE

Spark Therapeutics

$46.37

1.16 (2.57%)

ALK

Alaska Air

$70.83

1.44 (2.08%)

ORCL

Oracle

$48.30

-1.89 (-3.77%)

HUM

Humana

$253.64

3.03 (1.21%)

KND

Kindred Healthcare

$8.60

0.45 (5.52%)

  • 12

    Jan

  • 08

    Feb

  • 08

    Feb

NFLX Netflix
$190.12

0.56 (0.30%)

12/06/17
PIPR
12/06/17
NO CHANGE
Target $240
PIPR
Overweight
Piper sees high likelihood of Q4 subscriber upside for Netflix
Piper Jaffray analyst Michael Olson says his analysis of Netflix search trends suggests upside potential for both international and domestic subscriber in Q4. The analyst models 9.3% year-over-year domestic sub growth in Q4 while his search index points to 14.8% growth. For international, Olson models 38.7% year-over-year sub growth while his index points to 54.5% growth. The index is directionally positive and shows a high likelihood of Q4 subscriber upside for Netflix, Olson tells investors in a research note. He maintains an Overweight rating on the shares with a $240 price target.
12/13/17
BTIG
12/13/17
NO CHANGE
BTIG
Disney, Fox deal may be a near-term positive for Netflix, BTIG says
Commenting on Disney's (DIS) deal with Fox (FOX; FOXA) and its potential implications, BTIG's Richard Greenfield notes that the knee jerk reaction he hears across the investment world is the former is buying the later to build their "Netflix killer." Greenfield "strongly disagrees" with this viewpoint, saying that if Disney wanted to build a Netflix competitor it should be eliminating its stock buyback and aggressively investing in content that has no legacy media strings attached. Further, the Disney/Fox transaction is likely a near-to-intermediate term positive for Netflix, he argues, adding that both companies will be tied up in a 12 month or more regulatory review process with thousands of executives in limbo pending the closing of the transaction.
12/15/17
LOOP
12/15/17
NO CHANGE
Target $106
LOOP
Hold
Disney's Star Wars opening weekend estimated remains $225M, says Loop Capital
Loop Capital analyst David Miller keeps his Hold rating and $106 price target on Disney (DIS), forecasting the opening weekend box office for Star Wars: The Last Jedi at $225M, the ultimate domestic take of $850M, and global revenue of $1.7B. The analyst says the film was "awesome" - as good, if not better than The Force Awakens which cleared $2.07B in global box office. Miller also notes that Disney discussed the implications of the company taking managerial control over Hulu, saying CEO Bob Iger appeared non-committal on whether to use Hulu as the head-to-head competitor with Netflix (NFLX) or await its Direct-To-Consumer product to be launched in mid-2019.
12/06/17
12/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Alibaba (BABA) initiated with a Positive at Susquehanna. 2. WWE (WWE) initiated with an Overweight at JPMorgan. 3. Facebook (FB), Alphabet Class A (GOOGL), and Amazon.com (AMZN) were initiated with an Outperform at Evercore ISI, while Netflix (NFLX) was initiated with an In Line. 4. Applied Materials (AMAT) initiated with an Outperform at Wells Fargo. 5. Delphi Technologies (DLPH) was initiated with an Overweight at Barclays while being initiated with a Neutral at BofA/Merrill and UBS. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DIS Disney
$111.27

0.7 (0.63%)

12/15/17
EDJN
12/15/17
DOWNGRADE
EDJN
Hold
Disney downgraded to Hold from Buy at Edward Jones
Edward Jones analyst downgraded Disney (DIS) to Hold from Buy saying the acquisition of 21st Century Fox (FOXA) increase Disney's dependency on cable networks and adds various complexities. Additionally, the firm's analyst views Disney shares as fairly valued following recent share appreciation in light of the deal.
12/15/17
KEYB
12/15/17
DOWNGRADE
KEYB
Sector Weight
21st Century Fox downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Andy Hargreaves downgraded 21st Century Fox (FOXA) to Sector Weight saying that while he views the asset sale to Disney (DIS) as positive for both sides, regulatory risks are high. The analyst sees total potential value in the deal at $42 for Fox shares, but feels a discount is warranted given the regulatory risk. Hargreaves believes current fair value for Fox shares is $37.
12/15/17
WELS
12/15/17
NO CHANGE
Target $135
WELS
Outperform
Disney price target raised to $135 from $116 at Wells Fargo
Wells Fargo analyst Marci Ryvicker raised her price target for Disney (DIS) shares to $135 following the company's acquisition of 21st Century Fox (FOXA) assets. The analyst is positive on the deal and sees "significant potential upside" for Disney. She notes, however, that the new company is more complex given the consolidation of Hulu and addition of Sky. Ryvicker keeps Outperform rating on Disney shares.
FOXA 21st Century Fox
$34.99

0.11 (0.32%)

12/15/17
PIPR
12/15/17
NO CHANGE
Target $125
PIPR
Overweight
Piper raises price targets for both Disney and 21st Century Fox
Piper Jaffray analyst Stan Meyers raised his price target for Disney (DIS) shares to $125 from $120 and his target for 21st Century Fox (FOXA) shares to $40 from $35 following the yesterday's asset sale deal. The analyst has Overweight ratings on both names. He believes the transaction is mutually beneficial. Disney unlocks intellectual property value "better than anyone," and can extract better economics with counterparties via scale, while Fox's leaner structure allows it to rerate higher, execute on core competencies, and generate "significant" free cash flow for shareholders, Meyers tells investors in a research note.
FOX 21st Century Fox
$34.22

(0.00%)

12/13/17
FBNS
12/13/17
NO CHANGE
FBNS
FBN says Fox could be worth over $42 per share with Disney deal
With multiple media report indicating that Disney (DIS) is close to finalizing a deal to buy most of 21st Century Fox's (FOX) assets and operations, FBN Securities analyst Robert Routh is estimating that Fox shares could have a "real value" of $42.46 based on what has been reported on the likely deal. This estimate is before considering taxes and taking into account that Disney shares will likely rise after a deal is confirmed, said Routh, who does not officially cover either Disney or Fox.
12/11/17
BTIG
12/11/17
NO CHANGE
BTIG
BTIG says Comcast could pay 'significantly' more for Fox assets than Disney
BTIG analyst Richard Greenfield said earlier in a note to investors that he believes Comcast (CMCSA) could pay "significantly more" for the assets that Fox (FOXA) is reportedly looking to sell than could Disney (DIS). He also believes Comcast could have a better chance of securing regulatory approval for a deal if they are willing to spin off all of the regional sports networks that a combined entity would own.
11/10/17
BERN
11/10/17
NO CHANGE
Target $101
BERN
Market Perform
Disney deal for Fox wouldn't solve underlying problems, says Bernstein
Bernstein analyst Todd Juenger noted that Disney (DIS) has gone from a situation where reported EPS was going up but its stock price was going down to one where EPS is going down but the stock has been going up a bit driven by M&A speculation. However, he contends that the current round of renewed M&A speculation is happening because underlying fundamentals are "so bad" and even if a deal for Disney to buy Fox (FOXA) assets happens it wouldn't solve the underlying problems. He also thinks the chances of a Disney-Fox deal as currently described are "very low." Juenger maintains a Market Perform rating and $101 price target on Disney shares.
MSGN MSG Networks
$19.80

0.05 (0.25%)

10/11/17
LOOP
10/11/17
UPGRADE
Target $25
LOOP
Buy
MSG Networks upgraded to Buy from Hold at Loop Capital
Loop Capital analyst David Miller upgraded MSG Networks to Buy and raised his price target for the shares to $25 from $19. The company's free cash flow generation, both in the upcoming quarter and for all of fiscal year 2018, "will finally supercharge" its net debt/AOI ratio down to below 3.0 times by the end of the fiscal year, Miller tells investors in a research note. He believes the market is "underestimating the pace at which that will happen."
10/31/17
MSCO
10/31/17
DOWNGRADE
Target $20
MSCO
Underweight
MSG Networks downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne downgraded MSG Networks to Underweight from Equal Weight, stating that breaking up cable bundles may weigh on sports networks and he believes consensus expectations for EBITDA growth in FY19 and beyond look optimistic. The analyst, who assumes MSG Networks' long-term EBITDA declines, lowered his estimates and cut his price target on the stock to $20 from $24.
09/11/17
BTIG
09/11/17
NO CHANGE
Target $260
BTIG
Buy
Knicks sale would not be surprising after Rockets deal, says BTIG
BTIG analyst Brandon Ross noted that James Dolan and family have been actively unwinding their ties to the legacy TV bundle, both by splitting Madison Square Garden (MSG) from MSG Networks (MSGN) and via the sale of Cablevision to Altice (ATCEY). He also notes that Dolan is on record that he believes sports rights are in a bubble. Given all of this, and the recent big-ticket sale of the Houston Rockets, Ross would not be surprised to see Dolan consider a sale of the Knicks and/or Rangers, adding that selling one team or both could pave the way for an eventual "go-private" deal for the rest of MSG and its remaining live entertainment business. Ross keeps a Buy rating and $260 price target on Madison Square Garden shares.
08/30/17
FBNS
08/30/17
UPGRADE
Target $26.92
FBNS
Outperform
MSG Networks upgraded to Outperform from Sector Perform at FBN Securities
FBN Securities analyst Robert Rougth upgraded MSG Networks to Outperform with a price target of $26.92 saying shares now trade at 7.4x 2018 estimated AOI compared with his last note when equity was at 8.5x the same metric.
AMCX AMC Networks
$55.33

1.16 (2.14%)

10/12/17
10/12/17
DOWNGRADE
Target $105

Neutral
Disney downgraded to Neutral on increased pay-TV caution at Guggenheim
As previously reported, Guggenheim analyst Michael Morris downgraded Disney (DIS) to Neutral from Buy, citing his increased caution toward pay-TV trends and concern that expectations for the contribution from its content cycle are too high. While he is optimistic about the company's proposed direct-to-consumer streaming products, he expects the initial investment and long lead time into the launch to weigh on sentiment over the next 12 months, Morris tells investors. The analyst, who lowered his price target on Disney to $105 from $122, also downgraded Viacom (VIAB) and AMC Networks (AMCX) this morning.
10/12/17
10/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wal-Mart (WMT) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Matthew Fassler saying shares have achieved in three months what he had expected in a year on an improvement in sentiment, but not on higher earnings estimates. 2. Monro (MNRO) downgraded to Hold from Buy at Jefferies with analyst Bret Jordan citing expectations the company's earnings growth will slow in 2018 as its focus shifts from acquisitions to improving store-level execution. 3. Diamond Offshore (DO) downgraded to Sell from Neutral at Citi with analyst Scott Gruber saying that if an upturn is forthcoming, Transocean should outperform given a "diminution" of concern toward its balance sheet and more new contract catalysts. 4. Cummins (CMI) downgraded to Neutral following dealer checks at Longbow with analyst Faheem Sabeiha citing a recent truck dealer survey that suggests initial 2018 sales growth is below current industry forecasts, partly due to driver shortage concerns. 5. Disney (DIS), AMC Networks (AMCX), and Viacom (VIA, VIAB) were downgraded to Neutral from Buy at Guggenheim. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/12/17
GUGG
10/12/17
DOWNGRADE
GUGG
Neutral
AMC Networks downgraded to Neutral from Buy at Guggenheim
10/12/17
10/12/17
DOWNGRADE
Target $60

Neutral
AMC Networks downgraded to Neutral on ad growth concerns at Guggenheim
As previously reported, Guggenheim analyst Michael Morris downgraded AMC Networks to Neutral from Buy, citing his concern about advertising growth trends and increased pressure from digital video competitors. He now forecasts 2018 domestic advertising revenue will decline by 2.3%, with a 6.2% decline at flagship AMC, as The Walking Dead continues to mature and potentially lose audience, he tells investors. Morris lowered his price target on AMC Networks to $60 from $73.
VIAB Viacom
$30.24

0.53 (1.78%)

11/17/17
RBCM
11/17/17
NO CHANGE
Target $23
RBCM
Underperform
Viacom price target lowered to $23 from $30 at RBC Capital
RBC Capital analyst Steven Cahall lowered his price target on Viacom to $23 following Q4 results. Cahall says that despite the EPS beat, weaker domestic affiliate revenue growth was the latest surprising development as part of a trend of negative estimate revisions. The analyst keeps his Underperform rating, saying that investors are cautious on exposure to Media amid a "gravitational pull toward more visible growth stories", particularly as Viacom undergoes a period of strategic restructuring.
11/20/17
11/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying after dropping 16% since mid-January, "much of the bad news is behind the stock" in terms of wireless service revenue declines. 2. 3D Systems (DDD) upgraded to Neutral from Underweight at Piper Jaffray with analyst Troy Jensen saying he sees limited downside from current share levels. 3. Viacom (VIAB, VIA) upgraded to Hold from Sell at Deutsche Bank with analyst Bryan Kraft saying he sees limited room for further multiple compression. 4. Maxwell (MXWL) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying he sees consensus estimates as achievable for 2018, and merger synergies with NessCap should start making a more material contribution over the next few quarters. 5. National Beverage (FIZZ) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic citing his increased conviction on the sales and bottom-line upside of the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/29/17
KEYB
11/29/17
NO CHANGE
KEYB
Q3 results, analysis of Q4 viewership trends show some bright spots, says KeyBanc
KeyBanc analyst Andy Hargreaves notes that the Department of Justice's decision to sue to block AT&T (T)/Time Warner (TWX) seems likely to halt additional M&A until a resolution is reached. Additionally, the analyst points out that Q4 viewership trends appear most positive for Discovery (DISCA), Viacom (VIAB) so far, and 21st Century Fox (FOXA) remains his favorite long among TV network stocks.
11/20/17
DBAB
11/20/17
UPGRADE
Target $25
DBAB
Hold
Viacom upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Viacom to Hold saying he sees limited room for further multiple compression. The analyst believes reports of merger speculation in the media space should provide valuation support and he keeps a $25 price target for Viacom shares.
VIA Viacom
$34.40

0.25 (0.73%)

10/13/17
MSCO
10/13/17
NO CHANGE
Target $38
MSCO
Overweight
Viacom could be pushed back above $30 by Charter pact, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted press reports suggesting a negotiation going on between Viacom (VIAB) and Charter (CHTR) on a carriage agreement renewal and he is now modeling a nearly 15% one-time decline in blended affiliate fee pricing across Charter's footprint in exchange for broad distribution. If Viacom's networks get continued carriage on Charter, even with reduced fees, this could drive Viacom shares back above $30, contends Swinburne. He lowered his price target on Viacom to $38 from $42, but keeps an Overweight rating on the stock, noting that in any case the Charter relationship overhang will likely be removed by month end.
XOM Exxon Mobil
$83.03

0.13 (0.16%)

12/11/17
FBCO
12/11/17
INITIATION
FBCO
Neutral
Exxon Mobil initiated with a Neutral at Credit Suisse
Credit Suisse analyst William Featherston initiated Exxon Mobil with a Neutral rating and $83 price target.
11/07/17
11/07/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Priceline (PCLN) downgraded to Neutral from Buy at Guggenheim. 2. Exxon Mobil (XOM) downgraded to Reduce from Hold at HSBC with analyst Gordon Gray saying he compares Exxon's valuation to Buy rated Shell's (RDS.A) saying it is a third higher, yet Shell generated $7B more underlying cash flow in the past 12 months, and he thinks Exxon's capex will rise by much more in 2018 in comparison. 3. Teva (TEVA) downgraded to Reduce from Hold at HSBC with analyst Steve McGarry saying the balance sheet is "over-stretched." 4. Cabot Oil & Gas (COG) downgraded to Hold from Buy at Drexel Hamilton with analyst Bob Christensen citing the temporary stay issued on the Atlantic Sunrise pipeline. 5. SMIC (SMI) downgraded to Underperform from Neutral at Credit Suisse. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/12/17
12/12/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mylan (MYL), Teva (TEVA) and Endo (ENDP) initiated with a Neutral at Gugenheim, while Impax (IPXL) was initiated with a Buy. 2. Stitch Fix (SFIX) initiated with an Outperform at William Blair, a Neutral at JPMorgan and Goldman Sachs, an Overweight at Piper Jaffray, an Equal Weight at Barclays and a Hold at Stifel. 3. Exxon Mobil (XOM) and ConocoPhillips (COP) initiated with a Neutral at Credit Suisse. The firm also started Range Resources (RRC) and Anadarko (APC) with an Outperform, and Laredo Petroleum (LPI), Energen (EGN), Southwestern Energy (SWN), Noble Energy (NBL), Murphy Oil (MUR), Cabot Oil & Gas (COG) and Newfield Exploration (NFX) with a Neutral rating. 4. Restaurant Brands (QSR) initiated with an Outperform at Evercore ISI. 5. Waste Connections (WCN) initiated with an Outperform, named a top pick at BMO Capital. This list is just a portion of The Fly's full analyst coverage. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/17
RBCM
11/16/17
NO CHANGE
Target $85
RBCM
Sector Perform
Exxon Mobil price target lowered to $85 from $90 at RBC Capital
RBC Capital analyst Biraj Borkhataria lowered the price target on Exxon Mobil to $85 and kept his Sector Perform rating. Borkhataria says that while the company's dividend yield is attractive historically, there is limited scope for the company to raise is share buybacks materially given that its surplus cash will likely be used to fund asset acquisitions.
ONCE Spark Therapeutics
$46.37

1.16 (2.57%)

12/13/17
BERN
12/13/17
NO CHANGE
Target $71
BERN
Outperform
Spark Therapeutics price target lowered to $71 from $90 at Bernstein
Bernstein analyst Vincent Chen lowered his price target for Spark Therapeutics to $71 from $90 after the disappointing hemophilia A data at ASH. The analyst reiterates an Outperform rating on the shares.
12/14/17
GSCO
12/14/17
DOWNGRADE
Target $58
GSCO
Neutral
Goldman downgrades Spark Therapeutics on lack of 2018 catalysts
Goldman Sachs analyst Salveen Richter downgraded Spark Therapeutics to Neutral from Buy and cut his price target for the shares to $58 from $106. The analyst sees limited "value-driving" catalysts in 2018. Richter expects Luxturna to receive U.S. approval by January 12 with a "decent likelihood" of a successful launch, but estimates this program is already reflected in the valuation. Further, he believes SPK-8011 in hemophilia A lost its "spark" following the recent data readout. Richter this morning also upgraded GW Pharmaceuticals (GWPH) to Buy.
12/14/17
GSCO
12/14/17
DOWNGRADE
GSCO
Neutral
Spark Therapeutics downgraded to Neutral from Buy at Goldman Sachs
12/13/17
LEHM
12/13/17
NO CHANGE
Target $54
LEHM
Overweight
Spark Therapeutics selloff brings good entry point, says Barclays
Barclays analyst Gena Wang believes this week's selloff in shares of Spark Therapeutics has brought a good entry point. The risk/reward is favorable as hemophilia A seems largely removed from the valuation, Wang tells investors in a research note. She believes current data are limited and likely too early to suggest complete dismissal of the program. The analyst lowered her price target for Spark shares to $54 from $107 and removed the stock as her Top Pick. Wang, however, keeps an Overweight rating on the name.
ALK Alaska Air
$70.83

1.44 (2.08%)

12/04/17
COWN
12/04/17
NO CHANGE
Target $89
COWN
Outperform
Alaska Air a top pick for 2018, says Cowen
Cowen analyst Helane Becker is calling Alaska Air a top pick for 2018. She said the current share price fully reflects the operational missteps and pricing pressure from substantial growth in 2017. She believes there are catalysts to drive the shares higher, including taking market share form other larger carriers. Becker reiterated her Outperform rating and $89 price target on Alaska Air shares.
12/14/17
RAJA
12/14/17
NO CHANGE
RAJA
Raymond James Analysts' Best Picks for 2018
Raymond James named its Analysts' Best Picks for 2018. They are: Alaska Air (ALK), Alibaba (BABA), Becton Dickinson (BDX), Broadcom (AVGO), Continental Resources (CLR), Dollar Tree (DLTR), Fastenal (FAST), First Horizon (FHN), Flir Systems (FLIR), ICU Medical (ICUI), Progressive (PGR),ProPetro Holding (PUMP), ServiceNow (NOW), SS&C (SSNC), SVB Financial (SIVB), UnitedHealth (UNH), and Weyerhaeuser (WY).
11/15/17
11/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tyson Foods (TSN) upgraded to Buy from Hold at Argus with analyst John Staszak saying the company's wide range of food business offerings gives it an edge over less diversified competitors, adding that growing demand for meat products will result in better than expected operating income over the next two years. 2. Sangamo (SGMO) upgraded to Overweight from Neutral at Piper Jaffray with analyst Charles Duncan saying he sees a "reinvigorated" company with a reestablished clinical stage pipeline. 3. Alaska Air (ALK) upgraded to Strong Buy from Outperform at Raymond James with analyst Savanthi Syth saying risk/reward is compelling following the recent pullback. 4. Ingredion (INGR) upgraded to Overweight from Equal Weight at Stephens with analyst Farha Aslam saying she views the company being well positioned to deliver double-digit EPS growth given an improving product mix, recovery in South America, and cash flow that can be deployed for dealmaking or share repurchases. 5. Tesaro (TSRO) upgraded to Outperform from Market Perform at Leerink with analyst Seamus Fernandez citing more favorable risk/reward, particularly for longer term shareholders, and recent weakness in the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/17
MSCO
11/16/17
NO CHANGE
Target $78
MSCO
Overweight
Alaska Air named top pick in U.S. airlines at Morgan Stanley
Morgan Stanley analyst Rajeev Lalwani moved Alaska Air (ALK) up to be his top pick in the U.S. airline space, saying he has become more bullish on the stock given bottoming trends, solid relative fundamentals, and its discounted valuation following the selloff after its Q3 earnings report. Lalwani maintains an Overweight rating and $78 price target on Alaska Air.
ORCL Oracle
$48.30

-1.89 (-3.77%)

12/15/17
MSCO
12/15/17
NO CHANGE
Target $50
MSCO
Equal Weight
Oracle 'confounding' Cloud strategy likely caps multiple, says Morgan Stanley
Morgan Stanley analyst Keith Weiss said Oracle's license business is sustaining better than expected due to a more robust on-premise spending environment and the long-awaited 12c database cycle, but he notes that its Cloud revenues and margins missed expectations. The company's Cloud strategy "continues to confound investors," which will likely keep a near-term cap on the stock's multiple, contends Weiss, who raised his price target on Oracle to $50 from $47 but keeps an Equal Weight rating on the name.
12/15/17
12/15/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. RBC Capital analyst Ross MacMillan downgraded Oracle (ORCL) to Sector Perform from Outperform and lowered his price target to $51 from $53 after Q2 results. MacMillan says that while better near-term license sales prospects buffer software revenue, bigger license declines can be expected in Q4 and beyond based on the difficult comps and "maturing 12cR2 cycle". 2. JMP Securities analyst Andrew Boone downgraded Criteo (CRTO) to Market Perform from Outperform and Citi analyst Mark Kelley downgraded Criteo to Neutral, with both citing uncertainty around Apple's (AAPL) potential response to the company's workaround of the tech giant's Intelligent Tracking Prevention. 3. Stifel analyst Jim Duffy downgraded Fitbit (FIT) to Sell from Hold as he expects the company will remain unprofitable and burn cash in 2018. 4. JPMorgan analyst Andrea Teixeira downgraded e.l.f. Beauty (ELF) to Underweight, as she expects continued deterioration in sell-through rates in tracked channels to limit the company's ability to hit its 20%-plus long-term revenue growth target.5. Goldman Sachs analyst Jami Rubin removed Amgen (AMGN) from the Conviction Buy List but maintained a Buy rating on the stock. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/15/17
ADAM
12/15/17
NO CHANGE
Target $53
ADAM
Buy
Canaccord lowers Oracle price target to $53 after 'not that good' report
Canaccord analyst Richard Davis said Oracle's Q2 report was "not that good" and "confusing, to say the least." However, he said he is willing to give the company one more quarter to prove it has not become a value trap. Davis, who lowered his outlook on cloud revenue, cloud gross margins and overall operating margins following the report, keeps a Buy rating on Oracle but cut his price target on the shares to $53 from $57.
12/15/17
RBCM
12/15/17
DOWNGRADE
Target $51
RBCM
Sector Perform
Oracle downgraded to Sector Perform at RBC Capital on lower cloud revenue view
As reported earlier, RBC Capital analyst Ross MacMillan downgraded Oracle to Sector Perform from Outperform and lowered his price target to $51 from $53 after Q2 results. MacMillan says that while better near-term license sales prospects buffer software revenue, bigger license declines can be expected in Q4 and beyond based on the difficult comps and "maturing 12cR2 cycle". The analyst adds that he struggles to find potential catalysts amid more challenging competitive dynamics.
HUM Humana
$253.64

3.03 (1.21%)

12/06/17
COWN
12/06/17
NO CHANGE
COWN
Tax reform best for Medicare Advantage products, says Cowen
Cowen analyst Christine Arnold reviewed the tax reform implications for the managed care sector and believes the lower tax rate will be most beneficial for Medicare Advantage products as it could allow companies to offset a portion of the non-tax deductible headwind, allowing for stronger margins and/or enhanced benefits for seniors. She believes the lower tax rate would be most positive for Molina (MOH) and WellCare (WCG) given their domestic exposure, but it would also lead to a 15% earnings increase above her projections for Aetna (AET), Anthem (ANTM), Centene (CNC) and Humana (HUM).
11/10/17
BMOC
11/10/17
NO CHANGE
Target $290
BMOC
Outperform
Humana price target lowered to $290 from $300 at BMO Capital
BMO Capital analyst Matt Borsch lowered his price target on Humana to $290 following Q3 results to account for lower than expected initial FY18 EPS outlook. The analyst attributes some of the caution to increased competition in Medicare, but says the multi-year growth outlook remains strong. Borsch keeps his Outperform rating on Humana, saying the company also remains a possible acquisition target as the only Medicare Advantage pure play.
11/27/17
LEER
11/27/17
NO CHANGE
Target $280
LEER
Outperform
Cigna most likely acquirer of Humana in any potential transaction, says Leerink
Leerink analyst Ana Gupte notes that a Change of Control 8-K filed by Humana (HUM) suggests that the company is a possible take-out target after the Medicare Advantage Annual Enrollment Season, though the company maintains that this is a needed refresh with broader policy guidelines, rather than individually driven. The analyst sees Cigna (CI) as the most likely acquirer in any potential transaction and able to offer as much as 6% accretion in year 2 and 12% in year 3 post close. However, Anthem (ANTM) and even Wal-Mart (WMT) or Walgreens Boots Alliance (WBA) could be other dark horse acquirers, she contends. Gupte expects that Cigna would need to divest its legacy Health Spring MA assets to satisfy anti-trust regulators, with multiple possible buyers for the assets including WellCare (WCG), Aetna (AET) and Anthem. The analyst reiterates an Outperform rating and $280 price target on Humana shares.
12/13/17
COWN
12/13/17
NO CHANGE
Target $285
COWN
Outperform
Cowen calls Humana a best idea for 2018, ups target to $285
Cowen analyst Christine Arnold raised her price target for Humana to $285 from $275 and names the stock a best idea for 2018. The analyst expects Medicare Advantage enrollment growth to accelerate in 2018 and believes a lower corporate tax rate could meaningfully benefit the company's earnings. She keeps an Outperform rating on Humana.
KND Kindred Healthcare
$8.60

0.45 (5.52%)

07/26/17
MZHO
07/26/17
DOWNGRADE
MZHO
Neutral
Amedisys downgraded on 'massive' CMS reimbursement cut plan at Mizuho
As previously reported, Mizuho analyst Sheryl Skolnick downgraded Amedisys (AMED) to Neutral from Buy after the Centers for Medicare & Medicaid Services issued a proposed rule that would update the 2018 Medicare payment rates and the wage index for home health agencies, which she called a "body blow" that represents a significant headwind for the industry. The proposed new system not only would cut industry payments by $950M in 2019, but would also make LUPA reimbursement worse, she told investors. Skolnick lowered her price target for Amedisys to $50 from $65, cut her price target for HealthSouth (HLS) to $45 from $47 and trimmed her price target on Kindred Healthcare (KND) to $8 from $9.
07/26/17
STFL
07/26/17
NO CHANGE
STFL
CMS proposal negative for home health providers, says Stifel
Stifel analyst Chad Vanacore says that CMS proposed a 0.4% cut reduction in Medicare payments to home health agencies in 2018 and "potential deep cuts" in 2019. He views this development as negative for companies in the sector, "especially Kindred Healthcare (KND)." The analyst identifies Ensign Group (ENSG) and Brookdale Senior Living (BKD) as other affected companies in the sector. He keeps a Sell rating on Kindred, a Hold rating on Ensign ,and a Buy rating on Brookdale.
11/16/17
JPMS
11/16/17
NO CHANGE
JPMS
Neutral
Almost Family acquired for 16% premium, says JPMorgan
JPMorgan analyst Gary Taylor says Almost Family's (AFAM) merger of equals with LHC Group (LHCG) amounts to a takeover at a 16% premium, based on LHC's closing price yesterday. Regarding antitrust, the analyst notes that while the deal would propel the third and fourth largest players in the home-health industry to a number two position behind Kindred Healthcare (KND), the industry is "tremendously fragmented." Further, Taylor believes the merger agreement contains "onerous divestiture language." The analyst has a Neutral rating on Almost Family with a $59 price target.
11/20/17
STFL
11/20/17
UPGRADE
Target $7
STFL
Hold
Kindred Healthcare upgraded to Hold from Sell at Stifel
Stifel analyst Chad Vanacore upgraded Kindred Healthcare to Hold from Sell, stating that he expects the share price and earnings to remain volatile but much of the downside has been captured. The company's margins should be aided by the exit of its skilled nursing business, but Vanacore thinks additional significant cost savings will be needed to reach management's targets, he tells investors. He maintains a $7 price target on Kindred Healthcare shares.

TODAY'S FREE FLY STORIES

KORS

Michael Kors

$68.63

0.25 (0.37%)

, LULU

Lululemon

$106.18

-0.19 (-0.18%)

11:07
05/26/18
05/26
11:07
05/26/18
11:07
Periodicals
Dollar Tree looks interesting, Barron's says »

Next week, another 20…

KORS

Michael Kors

$68.63

0.25 (0.37%)

LULU

Lululemon

$106.18

-0.19 (-0.18%)

GME

GameStop

$12.64

-0.1 (-0.78%)

DLTR

Dollar Tree

$95.23

0.59 (0.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 12

    Jun

  • 14

    Jun

  • 26

    Jun

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

, QCOM

Qualcomm

$59.95

0.85 (1.44%)

10:58
05/26/18
05/26
10:58
05/26/18
10:58
Periodicals
Kraft Heinz, J&J among safe, 'solid' dividend stocks, Barron's says »

Kraft Heinz (KHC),…

KHC

Kraft Heinz

$57.78

0.72 (1.26%)

QCOM

Qualcomm

$59.95

0.85 (1.44%)

MRK

Merck

$59.08

-0.03 (-0.05%)

TGT

Target

$71.22

0.28 (0.39%)

OMC

Omnicom

$71.98

-0.1 (-0.14%)

CCL

Carnival

$64.27

0.12 (0.19%)

JNJ

Johnson & Johnson

$121.40

0.06 (0.05%)

MMM

3M

$198.98

-0.38 (-0.19%)

LLY

Eli Lilly

$82.75

0.05 (0.06%)

VLO

Valero

$118.81

-3.06 (-2.51%)

EMR

Emerson

$72.50

-0.77 (-1.05%)

WBA

Walgreens Boots Alliance

$63.52

0.09 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

  • 30

    May

  • 02

    Jun

  • 04

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 19

    Jun

  • 10

    Sep

  • 23

    Oct

MU

Micron

$61.33

-0.15 (-0.24%)

10:48
05/26/18
05/26
10:48
05/26/18
10:48
Periodicals
Micron can solve low valuation, Barron's says »

Micron's stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ATUS

Altice USA

$18.50

-0.05 (-0.27%)

10:40
05/26/18
05/26
10:40
05/26/18
10:40
Periodicals
Altice's spinoff could be winning bet, Barron's says »

On June 8, Altice will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

  • 30

    May

MU

Micron

$61.33

-0.15 (-0.24%)

, XLNX

Xilinx

$69.63

0.88 (1.28%)

10:35
05/26/18
05/26
10:35
05/26/18
10:35
Periodicals
AI revolution just getting started, Barron's says »

Artificial Intelligence…

MU

Micron

$61.33

-0.15 (-0.24%)

XLNX

Xilinx

$69.63

0.88 (1.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 20

    Jun

ZTCOY

ZTE Corp.

$0.00

(0.00%)

, DDAIF

Daimler AG

$0.00

(0.00%)

08:08
05/26/18
05/26
08:08
05/26/18
08:08
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

ZTCOY

ZTE Corp.

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

HMC

Honda

$32.04

-0.34 (-1.05%)

NSANY

Nissan

$0.00

(0.00%)

F

Ford

$11.51

-0.11 (-0.95%)

GM

General Motors

$38.30

-0.09 (-0.23%)

TM

Toyota

$129.97

-2.47 (-1.87%)

VLKAY

Volkswagen

$0.00

(0.00%)

BAC

Bank of America

$30.16

-0.03 (-0.10%)

C

Citi

$68.42

-0.86 (-1.24%)

GS

Goldman Sachs

$235.05

-1.1 (-0.47%)

JPM

JPMorgan

$110.62

-0.64 (-0.58%)

MS

Morgan Stanley

$53.02

-0.96 (-1.78%)

USB

U.S. Bancorp

$50.54

-0.14 (-0.28%)

WFC

Wells Fargo

$54.91

0.25 (0.46%)

TWTR

Twitter

$33.64

0.11 (0.33%)

AA

Alcoa

$47.92

-1.26 (-2.56%)

CENX

Century Aluminum

$16.27

-0.07 (-0.43%)

AOBC

American Outdoor Brands

$12.53

0.05 (0.40%)

RGR

Sturm, Ruger

$63.10

0.5 (0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 30

    May

  • 01

    Jun

  • 06

    Jun

  • 20

    Jun

  • 22

    Jun

  • 13

    Jul

  • 27

    Jul

  • 10

    Sep

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 15

    Jul

  • 15

    Oct

HCLP

Hi-Crush Partners

$13.20

-0.825 (-5.88%)

17:54
05/25/18
05/25
17:54
05/25/18
17:54
Hot Stocks
Hi-Crush Partners provides update on bulldozer incident in Whitehall facility »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POST

Post Holdings

$77.98

1.49 (1.95%)

17:37
05/25/18
05/25
17:37
05/25/18
17:37
Hot Stocks
Post Holdings reports fire in Michael Foods' plant in Pennsylvania »

Post Holdings reported a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:34
05/25/18
05/25
17:34
05/25/18
17:34
Hot Stocks
Abiomed to enter S&P 500 index on May 31 »

S&P MidCap 400…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

PRAH

PRA Health

$81.19

0.33 (0.41%)

GME

GameStop

$12.64

-0.1 (-0.78%)

FRED

Fred's

$1.69

0.05 (3.05%)

PRSP

Symbol now PB

$0.00

(0.00%)

RRTS

Roadrunner

$2.19

0.04 (1.86%)

DXC

DXC Technology

$94.20

-5.42 (-5.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 05

    Jun

  • 12

    Jun

PRAH

PRA Health

$81.19

0.33 (0.41%)

, ABMD

Abiomed

$394.49

0.04 (0.01%)

17:24
05/25/18
05/25
17:24
05/25/18
17:24
Hot Stocks
Breaking Hot Stocks news story on PRA Health, Abiomed »

PRA Health to replace…

PRAH

PRA Health

$81.19

0.33 (0.41%)

ABMD

Abiomed

$394.49

0.04 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

WYN

Wyndham

$107.98

-0.58 (-0.53%)

, MSCC

Microsemi

$68.74

0.005 (0.01%)

17:23
05/25/18
05/25
17:23
05/25/18
17:23
Hot Stocks
Breaking Hot Stocks news story on Wyndham, Microsemi »

Wyndham to replace…

WYN

Wyndham

$107.98

-0.58 (-0.53%)

MSCC

Microsemi

$68.74

0.005 (0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21
Hot Stocks
Breaking Hot Stocks news story on Abiomed, Wyndham »

ABIOMED to replace…

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 05

    Jun

  • 12

    Jun

PCG

PG&E

$44.67

0.84 (1.92%)

17:16
05/25/18
05/25
17:16
05/25/18
17:16
Periodicals
CA Forestry Dept rules PG&E equipment responsible for wildfires, Bloomberg says »

Report filed by…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FARM

Farmer Bros.

$28.50

0.15 (0.53%)

17:09
05/25/18
05/25
17:09
05/25/18
17:09
Hot Stocks
Levin Capital Strategies reports 8.4% stake in Farmer Bros »

Levin Capital purchased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:07
05/25/18
05/25
17:07
05/25/18
17:07
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIN

Windstream

$1.22

-0.125 (-9.29%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Hot Stocks
Windstream completes one-for-five reverse stock split »

Windstream completed its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NDLS

Noodles & Company

$8.90

-0.35 (-3.78%)

17:06
05/25/18
05/25
17:06
05/25/18
17:06
Syndicate
Breaking Syndicate news story on Noodles & Company »

Noodles & Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPD

Enterprise Products

$27.87

-0.12 (-0.43%)

17:01
05/25/18
05/25
17:01
05/25/18
17:01
Hot Stocks
Enterprise Products conduts open season for West Texas Crude oil expansion »

Enterprise Products…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INO

Inovio

$4.89

0.06 (1.24%)

16:37
05/25/18
05/25
16:37
05/25/18
16:37
Syndicate
Breaking Syndicate news story on Inovio »

Inovio files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$10.14

0.13 (1.30%)

16:36
05/25/18
05/25
16:36
05/25/18
16:36
Hot Stocks
Rent-A-Center 16.8% shareholder Engaged Capital nominates Carol McFate to Board »

On May 25, 2018, Engaged…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$0.59

0.0086 (1.48%)

16:34
05/25/18
05/25
16:34
05/25/18
16:34
Hot Stocks
Akers Biosciences receives delinquency notice from NASDAQ »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DHCP

Ditech

$6.60

0.37 (5.94%)

16:31
05/25/18
05/25
16:31
05/25/18
16:31
Hot Stocks
Ditech discloses receipt of late filing notice from NYSE »

Ditech Holding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$28.15

-4.82 (-14.62%)

, FL

Foot Locker

$55.97

9.585 (20.67%)

16:30
05/25/18
05/25
16:30
05/25/18
16:30
General news
On The Fly: Top stock stories for Friday »

Stocks on Wall Street…

GPS

Gap

$28.15

-4.82 (-14.62%)

FL

Foot Locker

$55.97

9.585 (20.67%)

HLF

Herbalife Nutrition

$48.76

-5.09 (-9.45%)

IEP

Icahn Enterprises

$69.41

0.22 (0.32%)

FCAU

Fiat Chrysler

$21.82

-0.445 (-2.00%)

DGX

Quest Diagnostics

$105.89

5 (4.96%)

UNH

UnitedHealth

$244.96

2.23 (0.92%)

ROST

Ross Stores

$77.35

-5.6 (-6.75%)

ADSK

Autodesk

$132.80

-5.96 (-4.30%)

AAL

American Airlines

$44.89

1.34 (3.08%)

LUV

Southwest

$52.86

1.65 (3.22%)

DAL

Delta Air Lines

$55.89

1.48 (2.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    May

  • 30

    May

  • 30

    May

  • 12

    Jun

  • 13

    Jun

  • 14

    Jun

  • 26

    Jun

  • 29

    Jun

16:30
05/25/18
05/25
16:30
05/25/18
16:30
Options
Preliminary option volume of 16.4M today »

Preliminary option volume…

VTL

Vital Therapies

$5.65

-0.475 (-7.76%)

16:26
05/25/18
05/25
16:26
05/25/18
16:26
Syndicate
Breaking Syndicate news story on Vital Therapies »

Vital Therapies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.